Cargando…
Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan
OBJECTIVE: To determine population-based estimates of coronavirus disease 2019 (COVID-19) in a densely populated urban community of Karachi, Pakistan. METHODS: Three cross-sectional surveys were conducted in April, June and August 2020 in low- and high-transmission neighbourhoods. Participants were...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752032/ https://www.ncbi.nlm.nih.gov/pubmed/33737137 http://dx.doi.org/10.1016/j.ijid.2021.03.040 |
Sumario: | OBJECTIVE: To determine population-based estimates of coronavirus disease 2019 (COVID-19) in a densely populated urban community of Karachi, Pakistan. METHODS: Three cross-sectional surveys were conducted in April, June and August 2020 in low- and high-transmission neighbourhoods. Participants were selected at random to provide blood for Elecsys immunoassay for detection of anti-severe acute respiratory syndrome coronavirus-2 antibodies. A Bayesian regression model was used to estimate seroprevalence after adjusting for the demographic characteristics of each district. RESULTS: In total, 3005 participants from 623 households were enrolled in this study. In Phase 2, adjusted seroprevalence was estimated as 8.7% [95% confidence interval (CI) 5.1–13.1] and 15.1% (95% CI 9.4–21.7) in low- and high-transmission areas, respectively, compared with 0.2% (95% CI 0–0.7) and 0.4% (95% CI 0–1.3) in Phase 1. In Phase 3, it was 12.8% (95% CI 8.3–17.7) and 21.5% (95% CI 15.6–28) in low- and high-transmission areas, respectively. The conditional risk of infection was 0.31 (95% CI 0.16–0.47) and 0.41 (95% CI 0.28–0.52) in low- and high-transmission neighbourhoods, respectively, in Phase 2. Similar trends were observed in Phase 3. Only 5.4% of participants who tested positive for COVID-19 were symptomatic. The infection fatality rate was 1.66%, 0.37% and 0.26% in Phases 1, 2 and 3, respectively. CONCLUSION: Continuing rounds of seroprevalence studies will help to improve understanding of secular trends and the extent of infection during the course of the pandemic. |
---|